Native and synthetic ferritins for nanobiomedical applications: Recent advances and new perspectives

Future Medicinal Chemistry

Volumn 2, Issue 4, 2010, Pages 609-618

  Domnguez Vera, José M ^a   Fernndez, Belén ^a   Glvez, Natividad ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; OLIGOMER;

BIOMEDICINE; COMPUTER ASSISTED TOMOGRAPHY; ELECTRON MICROSCOPY; FENTON REACTION; HISTOGRAM; NANOMEDICINE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SAMPLE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

FERRITINS; HUMANS; IRON; MODELS, MOLECULAR; NANOMEDICINE; OXIDATION-REDUCTION; PROTEIN CONFORMATION; QUANTUM DOTS;

EID: 77953417897     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.171     Document Type: Review

References (84)

1. Dallman PR. Biochemical basis for the manifestations of iron deficiency. Annu. Rev. Nutr. 6, 13-40 (1986).
2. Andrews NC. Disorders of iron metabolism. N. Engl. J. Med. 341, 1986-1995 (1999).
3. Winterbourn CC. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicology Letters 82/83, 969-974 (1995).
4. Corbett JV. Accidental poisoning with iron supplements. Am. J. Matern. Child. Nurs. 20, 234-237 (1995).
5. Barton JC, Bertoli LF, Hemochromatosis: the genetic disorder of the twenty first century. Nat. Med. 2, 394-395 (1996).
6. Karlberg T, Schagerlof U, Gakh O et al. The structure of frataxin oligomers reveal a novel mechanism for the delivery and detoxification of iron. Structure 14, 1535-1546 (2006).
7. Boldt DH. New perspectives on iron: an introduction. Am. J. Med. Sci. 318, 207-212 (1999).
8. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biol. Med. 23, 134-147 (1997).
9. Perry G, Cash AD, Smith MA. Alzheimer's disease and oxidative stress. J. Biomed. Biotechnol. 2, 120-123 (2002).
10. Harrison P, Arosio, P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochem. Biophys. Acta. 1275, 161-203 (1996).
11. Proulx-Curry PM. Chasteen ND, Molecular aspects of iron uptake and storage in ferritin. Coord. Chem. Rev. 144, 347-368 (1995).
12. Chasteen N, Harrison P. Mineralization in ferritin: an efficient means of iron storage. J. Struct. Biol. 126, 182-194 (1999).
13. Lawson DM, Treffry A, Artymiuk PJ et al. Identification of the ferroxidase centre in ferritin. FEBS Lett. 254(1-2), 207-210 (1989).
14. Levi S, Salfeld J, Franceschinelli F, Cozzi A, Dorner MH, Arosio, P. Expression and structural and functional properties of human ferritin .chain from Escherichia coli. Biochemistry 28(12), 5179-5184 (1989).
15. Bauminger ER, Harrison PM, Hechel D et al. Iron (II) oxidation and early intermediates of iron-core formation in recombinant human H-chain ferritin. Biochem J. 296(3), 709-719 (1993).
16. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63, 793-807 (1994).
17. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Park. Dis. Dement. Sect. 2, 327-340 (1990).
18. Linert W, Jameson GNL. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's disease. J. Inorg. Biochem. 79, 319-326 (2000).
19. Nunomura A, Perry G, Aliev G et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 759-767 (2001).
20. Smith MA, Perry G, Richey PL et al. Oxidative damage in Alzheimer's. Nature 382, 120-121 (1996).
21. Burdo JR, Connor JR. Brain iron uptake and homeostatic mechanisms: an overview. Biometals 16(1), 63-75 (2003).
22. Quintana C, Cowley JM, Marthic C, Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J. Struct. Biol. 147, 166-178 (2004).
23. Dobson, J. Magnetic iron compounds in neurological disorders Ann. NY Acad. Sci. 1012, 183-192 (2004).
24. Quintana C. Contribution of analytical microscopies to human neurodegenerative diseases research (PSP and AD). Mini Rev. Med. Chem. 7, 961-975 (2007).
25. Douglas BK. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Medical Genomics, 2, 2 (2009).
26. Berg D, Becker G, Riederer P, Rie O. Iron in neurodegenerative disorders. Neurotox. Res. 4, 637-653 (2002).
27. Clemente-León M, Coronado E, Soriano- Portillo A et al. Magnetic langmuir-blodgett films of ferritin with different iron contents. Langmuir 22, 6993-7000 (2006).
28. Gálvez N, Fernández B, Sánchez P et al. Comparative structural and chemical studies of ferritin cores with gradual removal of their iron contents. J. Am. Chem. Soc. 130, 8062-8068 (2008).
29. Collingwood J, Dobson J. Mapping and characterization of iron compounds in Alzheimer's tissue. J. Alzheimer's Dis. 10, 215-222 (2006).
30. Pankhursta Q, Hautotb D, Khanc N, Dobsonb J. Increased levels of magnetic iron compounds in Alzheimer's disease. J. Alzheimer's Dis. 13, 49-52 (2008).
31. Collingwood JF, Chong RKK, Kasama T et al. Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core. Mat. J. Alzheimer's Dis. 14, 235-245 (2008).
32. Uchida M, Klem MT, Allen M et al. Biological containers: protein cages as multifunctional nanoplatforms. Advanced Mater. 19(8), 1025-1042 (2007).
33. Lee LA, Wang Q. Adaptations of nanoscale viruses and other protein cages for medical applications. Nanomedicine 2, 137-149 (2006).
34. Laurent S, Forge D, Port M et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 108(6) 2064-2110 (2008).
35. Cheon J, Lee JH. Synergistically integrated nanoparticles as multimodal probes for nanobiotechnology. Acc. Chem. Res. 41 (12) 1630-1640 (2008).
36. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17, 545-580 (2003).
37. Mornet S, Vasseur S, Grasset F, Duguet E. Magnetic nanoparticle design for medical diagnosis and therapy. J. Mat. Chem. 14, 2161-2175 (2004).
38. Polyak B, Friedman G. Magnetic targeting for site - specific drug delivery: applications and clinical potential. Expert. Opin. Drug Deliv. 6, 53-70 (2009).
39. Dobson J. Magnetic nanoparticles for drug delivery. Drug Devel. Res. 67, 55-60 (2006).
40. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 53, 283-318 (2001).
41. Berry C, Curtis ASG. Functionalisation of magnetic nanoparticles for applications in biomedicine. J. Phys. D Appl. Phys. 36, 198-206 (2003).
42. Zhang Y, Li Y, Kim W, Wang D, Dai H. Imaging as-grown single-walled carbon nanotubes originated from isolated catalytic nanoparticles. Appl. Phys. A. Mater. Sci. Process. 74, 325-328 (2002).
43. Allen M, Willits D, Young M, Douglas T. Constrained synthesis of cobalt oxide nanomaterials in the 12-subunit protein cage from Listeria innocua. Inorg. Chem. 42(20), 6300-6305 (2003).
44. Okuda M, Iwahori K, Yamashita I, Zhang Y, Yoshimura H. Fabrication of nickel and chromium nanoparticles using the protein cage of apoferritin. Biotechnol. Bioeng. 84, 187-193 (2003).
45. Wong KKW, Mann S. Biomimetic synthesis of cadmium sulfide-ferritin nanocomposites. Adv. Mater. 8, 928-933 (1996).
46. Mann S, Archibald DD, Didymus JM et al. Transmission electron microscope investigation of cadmium sulfide nanoparticles grown under Langmuir monolayer. Science 261, 1286-1292 (1993).
47. Bulte JW. M. Douglas T, Mann S et al. Magnetoferritin: characterization of a novel super-paramagnetic MR contrast agent. J. Magn. Reson. Imag. 4, 497-505 (1994).
48. Douglas T, Bulte JWM, Dickson DPE et al. In: Hybrid Organic-Inorganic Composites. Mark JE, Lee CY-C, Bianconi PA (Eds). American Chemical Society, Washington, DC, USA, 19 (1995).
49. Wong KKW, Douglas T, Gider S, Awschalom DD, Mann S. Biomimetic synthesis and characterization of magnetic proteins (magnetoferritin) Chem. Mater. 10, 279-285 (1998).
50. Mann S, Meldrum FC. Controlled synthesis of inorganic materials using supramolecular assemblies. Adv. Mater. 3, 316-318 (1991).
51. Mackle P, Charnock CK, Garner CD, Meldrum FC, Mann S. Characterisation of the manganese core of reconstituted ferritin by x-ray absorption spectroscopy. J. Am. Chem. Soc. 115, 8471-8472 (1993).
52. Meldrum FC, Douglas T, Levi S, Arosio P, Mann S. Reconstitution of manganese oxide cores in horse spleen and recombinant ferritins. J. Inorg. Biochem. 58, 59-68 (1995).
53. Douglas T, Stark VT. Nanophase cobalt oxyhydroxide mineral synthesized within the protein cage of ferritin. Inorg. Chem. 39, 1828-1830 (2000).
54. Tsukamoto R, Iwahori K, Muraoka M, Yamashita I. Synthesis of CO3O4 nanoparticles using the cage-shaped protein, apoferritin. Bull. Chem. Soc. Jpn 78, 2075-2081 (2005).
55. Okuda M, Kobayashi Y, Suzuki K et al. Self-organized inorganic nanoparticle arrays on protein lattices. Nano. Lett. 5, 991-993 (2005).
56. Douglas T, Dickson DPE. Betteridge S, Charnock J, Garner CD, Mann S. Magnetoferritin: in vitro synthesis of a novel magnetic protein. Science 269, 54-57 (1995).
57. Yamashita I, Hayashi J, Hara M. Bio-template synthesis of uniform CdSe nanoparticles using cage-shaped protein, apoferritin. Chem. Lett. 33, 1158-1159 (2004).
58. Mayes EL. Self assembled nanoparticulate Co:Pt for data storage applications. IEEE Trans. Magn. 36, 3009-3011 (2000).
59. Iwahori K, Yoshizawa K, Muraoka M, Yamashita I. Fabrication of ZnSe nanoparticles in the apoferritin cavity by designing a slow chemical reaction system. Inorg. Chem. 44, 6393-6400 (2005).
60. Domínguez-Vera JM, Colacio E. Nanoparticles of prussian blue ferritin: a new route for obtaining nanomaterials. Inorg. Chem. 42, 6983-6985 (2003).
61. Aime S, Frullano L, Crich SG. Compartmentalization of a gadolinium complex in the apoferritin cavity: a route to obtain high relaxivity contrast agents for magnetic resonance imaging. Angew. Chem. Int. Ed. 41, 1017-1019 (2002).
62. Pead S, Durrant E, Webb B et al. Metal ion binding to apo, holo, and reconstituted horse spleen ferritin. J. Inorg. Biochem. 59(13), 15-27 (1995).
63. Gálvez N, Sánchez P, Domínguez-Vera JM. Preparation of Cu and CuFe prussian blue derivative nanoparticles using the apoferritin cavity as nanoreactor. Dalton Trans. 15, 2492-2494 (2005).
64. Douglas T, Ripoll DR. Calculated electrostatic gradients in recombinant human H-chain ferritin. Protein Sci. 7(5), 1083-1091 (1998).
65. Ueno T, Suzuki M, Goto T, Matsumoto T, Nagayama K, Watanabe Y. Size selective olefin hydrogenation by a pd nanocluster provided in the apo-ferritin cage Angew. Chem. Int. Ed. 43, 2527-2530 (2004).
66. Clemente-Leon M, Coronado E, Soriano- Portillo A, Galvez N, Dominguez-Vera JM. Permanent magnetism in apoferritin-encapsulated Pd nanoparticles. J. Mat. Chem. 17(1), 49-51 (2007).
67. Kramer RM, Li C, Carter DC, Stone MO, Naik RR. Engineered protein cages for nanomaterial synthesis. J. Am. Chem. Soc. 126, 13282-13286 (2004).
68. Ceolín M, Gálvez N, Sánchez MP, Fernández MB, Domínguez-Vera JM. Structural aspects of the growth mechanism of copper nanoparticles inside apoferritin. Eur. J. Inorg. Chem. 5, 795-801 (2008).
69. Galvez N, Sanchez P, Dominguez-Vera JM, Soriano- Portillo A, Clemente-Leon M, Coronado E. Apoferritin-encapsulated Ni and Co superparamagnetic nanoparticles. J. Mat. Chem. 16, 2757-2761 (2006).
70. Domínguez-Vera JM, Gálvez N et al. Size-controlled water-soluble Ag nanoparticles. Eur. J. Inorg. Chem. 30, 4823-4826 (2007).
71. Yang Z, Wang X, Diao X et al. Encapsulation of platinum anticancer drugs by apoferritin. Chem. Commun. 7(33), 3453-3455 (2007).
72. Uchida M, Terashima M, Cunningham CH et al. A human ferritin iron oxide nano-composite magnetic resonance contrast agent. Magn. Reson. Med. 60, 1073-1081 (2008).
73. Uchida M, Flenniken ML, Allen M et al. Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J. Am. Chem. Soc. 128, 16626-16633 (2006).
74. Li M, Wong KW, Mann S. Organization of inorganic nanoparticles using biotin- streptavidin connectors. Chem. Mater. 11, 23-26 (1999).
75. Danon D, Skutelsk E, Marikoversus Y, Goldstein L. Use of cationized ferritin as a label of negative charges on cell surfaces. J. Ultrastruct. Res. 38, 500-510 (1972).
76. Wong KK. W, Whilton NT, Colfen H, Douglas T, Mann S. Hydrophobic proteins: synthesis and characterization of organic-soluble alkylated ferritins. Chem. Commun. 76(3-4),1621-1622 (1998).
77. Wong KK. W. Colfen H, Whilton NT, Douglas T, Mann S. Synthesis and characterization of hydrophobic ferritin proteins. J. Inorg. Biochem. 76, 187-195 (1999).
78. Sano K, Ajima K, Iwahori K et al. Endowing a ferritin-like cage protein with high affinity and selectivity for certain inorganic materials. Small 1, 826-832 (2005).
79. Fernández B, Gálvez N, Sáchez P et al. Red and blue ferritin nanomagnets by dye-labeling to the protein shell. Inorganica Chimica Acta 360, 3951-3954 (2007).
80. Gálvez N, Fernández B, Sánchez P et al. Magnetic-fluorescent Langmuir-Blodgett films of fluorophore-labeled ferritin nanoparticle. Solid State Sci. 11, 754-759 (2009).
81. Fernández B, Gálvez N, Sánchez P, Cuesta R, Bermejo R, Domínguez-Vera JM. Fluorescence resonance energy transfer in ferritin labeled with multiple fluorescent dyes. J. Biol. Inorg. Chem. 13, 349-355 (2008).
82. Wang YA, Li JJ, Chen HY, Peng XG. Stabilize inorganic nanocrystals by organic dendrons. J. Am. Chem. Soc, 124, 2293-2298 (2002).
83. Green M, Howman E. Semiconductor quantum dots and free radical induced DNA nicking. Chem. Commun. 5, 121-123 (2005).
84. Fernández B, Gálvez N, Cuesta R, Hungría AB, Calvino JJ, Domínguez-Vera JM. Quantum dots decorated with magnetic bionanoparticles. Adv. Funct. Mater. 18, 3931-3935 (2008).